Antibody (Suitable for clinical applications)
Sample Type: FFPE Patient Samples.
Tested Applications: IHC. Approved for In Vitro Diagnostic Procedures on FFPE tissues. For tissue collection recommendations, please see datasheet sent with product.
Application Notes
| Specification | Recommendation |
|---|---|
| Recommended Dilution (Conc) | 1:50-1:100 |
| Pretreatment | EDTA Buffer pH 8.0 |
| Incubation Parameters | 30 min at Room Temperature |
Prior to use, inspect vial for the presence of any precipitate or other unusual physical properties. These can indicate that the antibody has degraded and is no longer suitable for patient samples. Please run positive and negative controls simultaneously with all patient samples to account and control for errors in laboratory procedure. Use of methods or materials not recommended by enQuire Bio including change to dilution range and detection system should be routinely validated by the user.
Clonality: Monoclonal
Anti-Cytokeratin 19 Antibody Clone: A53-B/A2.26
Host and Isotype: Mouse IgG2a, kappa
Recommended Positive Control Sample: Skin, Tonsil
Cellular Localization of Antibody A53-B/A2.26 Staining: Cytoplasmic
Buffer and Stabilizer: PBS with 1% BSA and 0.05% NaN3
Antibody Concentration: Lot specific. Plese contact tech support for data.
Immunogen: BALB/C mice were injected with human breast cancer MCF-7 cells.
Storage Conditions: This antibody should be stored refrigerated (2-8°C). This product should not be used past the expiration date printed on the vial.
Cytokeratin 19 Information for Pathologists
Summary:
Molecular weight is 40 kDa (smallest cytokeratin). Often coexpressed with CK7. Present in both simple and complex epithelium. Involved in the organization of myofibers; links contractile apparatus to dystrophin at costameres of striated muscle (also CK8, Mol Biol Cell 2005;16:4280). Polymorphisms of CK19 pseudogene are associated with primary biliary cirrhosis (Hepatol Res 2003;25:281).Common Uses By Pathologists:
Bladder: possible urine screening test for bladder carcinoma (J Egypt Natl Canc Inst 2006;18:82). Bone / soft tissue: distinguish chordoma (CK19+) from parachordoma (CK19-, Ann Diagn Pathol 1997;1:3). Breast: presence of CK19+ peripheral blood tumor cells or CK19+ fragments is a poor prognostic factor for breast cancer (predicts CNS relapse, Breast Cancer Res 2006;8:R36). Liver: distinguish hepatocellular carcinoma (CK19-) from either hepatoid adenocarcinoma metastatic to liver (CK19+, Am J Surg Pathol 2003;27:1302) or cholangiocarcinoma (CK19+, J Gastrointestin Liver Dis 2006;15:9, Am J Clin Pathol 2006;125:519). Liver: poor prognostic factor in hepatocellular carcinoma (Histopathology 2006;49:138, Cancer Sci 2003;94:851).Limitations and Warranty
This antibody is manufactured in accordance with clinical good manufacturing practices in an ISO13485:2016 certified production facility. It is intended for multiple uses including in vitro diagnostic use and research use only applications. Please see vial label for expiration date. We strive to always deliver antibodies with a shelf life of at least two years.
There are no reviews yet.